You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
McKesson
Baxter
Medtronic
Express Scripts

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Patent: 9,163,086

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,163,086
Title:Methods and compositions for the treatment of proliferative and pathogenic diseases
Abstract: The invention features proteins including an antibody, or functional derivatives thereof, that bind hCD59 and have the activity of domain 4 of the Streptococcus intermedins intermedilysin (ILY) protein. In order to prevent the independent induction of CDC and ADCC, the antibodies of the invention can bind the same hCD59 epitope as ILYd4 and/or contain modifications that disrupt the interaction between the antibody and complement.
Inventor(s): Qin; Xuebin (Westwood, MA), Hu; Weiguo (Quincy, MA)
Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA)
Application Number:13/391,124
Patent Claims:see list of patent claims

Details for Patent 9,163,086

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) 2029-08-18 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) 2029-08-18 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) 2029-08-18 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) 2029-08-18 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) 2029-08-18 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) 2029-08-18 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) 2029-08-18 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Moodys
Express Scripts
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.